Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Thursday Nov 19, 2009

DrStockPick.com Stock Report!

PWRM, PFE

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. PWRM’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). PWRM expects to complete phase II clinical validation trials of

...

Earlier this month, Medivation, Inc. (MDVN) and Pfizer, Inc. (PFE) initiated two phase III studies, CONTACT and CONSTELLATION, with Dimebon in patients with moderate-to-severe Alzheimer's disease (AD). Dimebon is being developed in collaboration with Pfizer for the treatment of Alzheimer’s and Huntington diseases. The CONTACT study will assess the potential benefits of adding Dimebon to ongoing treatment with Pfizer’s Aricept on neuropsychiatric symptoms and activities of daily living. Meanwhile, the CONSTELLATION study will evaluate the effects of adding Dimebon to Forest Lab’s (FRX) Namenda, another standard of care, on cognition, memory and activities of daily living. Preclinical studies indicate that Dimebon has the potential to protect brain cells from damage and enhance brain cell survival, by stabilizing and improving mitochondrial function. Dimebon’s mechanism is distinct from currently available Alzheimer’s medications. Dimebon is currently in seven studies which are evaluating the safety and efficacy ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Friday October 30, 2009

DrStockPick.com Stock Report!

PWRM, PFE

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

PFE, PWRM, BIIB

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase

...

The deal between Pfizer Inc. (PFE) and Wyeth was completed yesterday after the receipt of final regulatory approvals. Wyeth will cease to trade as an independent entity from today. Under the terms of the deal, Wyeth shareholders will receive $33 cash (without interest) and 0.985 Pfizer shares for every Wyeth share.   The cash-and-stock deal, which was valued at $68 billion when it was announced nine months ago, stood at about $66.9 billion based on Wednesday’s closing prices. Pfizer borrowed about $22.5 billion to this transaction. Pfizer expects the combined companies to realize synergies of about $4 billion by 2012. The deal is expected to be accretive to earnings by the second full-year following closing. Roughly one-half of the savings are expected to come from Selling General & Administrative costs with the balance coming from Research and Development. Pfizer intends to incrementally pay down the debt financing and ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday October 14, 2009

DrStockPick.com Stock Report!

PFE, PWRM, CSRH, MRK, CVAT, WFC, AQNM, WMT

**************************************************************

PFE, Pfizer Inc.

PFE engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.

PFE’s s $68 billion purchase of Wyeth will close Thursday after antitrust regulators in the U.S. and Canada cleared the deal.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening

...

Auxilium Pharma (AUXL) is currently awaiting a decision from the U.S. Food and Drug Administration (FDA) on its key pipeline candidate, Xiaflex, which is under FDA review for the treatment of Dupuytren’s Contracture. In September, Auxilium received a major boost in the form of a favorable recommendation from the FDA’s Arthritis Advisory Committee for Xiaflex for the treatment of Dupuytren’s Contracture.   Dupuytren’s Contracture is a condition that affects the connective tissue in the palm known as palmar fascia. The company estimates that approximately 240,000 Dupuytren’s candidates could exist in the U.S. and the EU. This represents significant commercial opportunity for Auxilium.   Xiaflex is also being studied for the treatment of Peyronie’s disease and frozen shoulder syndrome. According to the company, there are at least 450,000 potential patients annually in the U.S. and the EU for Dupuytren’s and Peyronie’s. Approval for both indications could help Xiaflex sales ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Tuesday September 29, 2009

DrStockPick.com Stock Report!

PFE, PWRM, TXN, CSRH, AA, CVAT, DOW

**************************************************************

PFE, Pfizer Inc.

PFE is the world’s premier biopharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals.

China’s Ministry of Commerce has approved PFE’s pending acquisition of Wyeth. The Ministry’s decision includes PFE’s commitment to divest certain animal health assets in China.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways,

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Friday September 25, 2009

DrStockPick.com Stock Report!

PWRM, PFE, NVS

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II

...

FDA advisory panel has backed and given a green signal to Auxilium Pharmaceutical’s experimental Xiaflex therapy which cures Dupuytren’s contracture. The FDA panel has stated that the Xiaflex therapy is absolutely effective and safe and a better alternative to surgery as a treatment for a condition that affects the connective tissues in the hand. With this approval by FDA, Auxilium’s share prices have been stable for sometime as investors are waiting for what’s the next step, to make sure they have invested in the right place at the right time. This is not only a good news for Auxilium Pharmaceuticals but also ...